Can you present your business and history in a few words, as well as in the field of activity in which you exercise? How did you become the world leader in radiopharmaceutical products?
Curium is the world leader in radiopharmaceutical products. These are advanced technologies products, which associate a radioactive element with a chemical marker. They are used to diagnose a wide variety of pathologies, including cardiac and respiratory, as well as cancers, and recently to treat certain types of cancers.
The name “Curium” pays tribute to the inheritance of Marie and Pierre Curie, pioneers in terms of radioactivity and that gave its name to the radioactive element Curium. The group was born from the merger in 2017 of the European leader was molecular and the American leader Mallinckrodt, both pioneers of nuclear medicine since the 1960s.
Our world leadership is based on this proven inheritance, on our product portfolio (the widest in the world) and our unique control of the supply chain, which allows us to deliver thousands of patients, every day and worldwide, extremely complex radioactive products to manufacture and transport, some of which should be injected with patients in less than 2 hours.
Do you have some figures to give about the growth and activity of your group internationally?
Each year, Curium provided diagnostic products and therapy to more than 14 million patients worldwide. Our 5,000 employees are present everywhere in Europe, in the United States and more recently in Japan, where we have signed a joint company with Peptidream, the Japanese leader in radiopharmaceutical products, and in Turkey, where we have just acquired the main player in the sector, Monrol. Our products are distributed throughout fifty countries worldwide through distributors.
What challenges do you face in this market?
The nuclear medicine market is in full transformation. From the 1960s to the early 2020s, nuclear medicine focused on the diagnosis of many cardiac and respiratory pathologies, as well as cancers. Innovation was very limited.
In recent years, nuclear medicine has been demonstrated as advanced oncological diagnostic technologies, as well as in the treatment of various types of cancer, particularly prostate cancer and neurdocrine tumors. Now there is a scientific consensus on the fact that radiopharmaceutical products could be lent to the treatment of about 80 % of cancers in the coming decade.
Therefore, the potential of nuclear medicine has exploded since the early 2020, the actors in the sector must now be successful in developing the right products for good pathologies and then making them available to doctors and patients around the world.
Design, develop, test and market innovative products, thanks to advanced innovation technologies, in a process that takes on average 10 years, from the concept to marketing, it is a great challenge for our sector.
In what place innovation in your business today?
Innovation is in the heart of the Curium project: today, the company reinvested all its profits in cancer research. At this time, two therapy products (against prostate cancer and neurodocrine tumors) and a diagnostic product (prostate cancer) are in the final human test on human scale in the United States. More than a dozen other products are in development, in previous stages, always in the field of oncology.
Our teams of researchers gather disciplines as varied as strong: experts in peptide chemistry, radio, oncobiologists, bioestadistists, nuclear doctors, oncologists, etc.
We have in our sites in France, the Netherlands, Finland and the United States of unique advanced equipment and very complex authorizations to obtain regulators that allow us to develop these advanced products.
Finally, what are the main values of your business to carry out this activity?
Curium commitment: redefine the experience of cancer, thanks to our recognized experience in nuclear medicine
Redefine cancer experience:
- New tools for better cancer understanding and a easier, previous and more precise diagnosis
- Directed, measurable and less painful treatments
- Transform the life of each patient we know
Our recognized experience in nuclear medicine:
- Unmatched knowledge, knowledge and global infrastructure in terms of nuclear medicine
- The world leader in radiopharmaceutical products
- Solutions that transform the lives of thousands of patients every day
BFM Business editorial staff did not participate in the realization of this content in association with Scribo. The consultation of this article is remarkably subject to the Scribo CGU.
Source: BFM TV
